 |
 |
 .gif){kind=small}  |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
| |||||||||||||||
|
Inquiry into Eli Lilly's practices David Teather in New York Friday March 26, 2004 The Guardian Eli Lilly, the US pharmaceutical firm, yesterday said US prosecutors were investigating the company's marketing practices for certain of its best selling
The company said the US attorney in its home state of Pennsylvania had informed it of the inquiry in the past few days. An Eli Lilly spokeswoman said the company understood the investigation was focused on Prozac and two other products, Evista, which fights osteoporosis, and Zyprexa, the world's leading schizophrenia medicine. Zyprexa was the company's highest selling product last year, generating revenues of $4.3bn. Eli Lilly has been under investigation by the US department of justice since 2002 for its methods of marketing Evista to doctors. The justice department issued a second subpoena for documents related to Evista in July. Pennsylvania officials recently filed a lawsuit against 13 drug companies, alleging that they offered doctors kickbacks for prescribing. Special reports Medicine and health Useful links British Medical Association Department of Health General Medical Council Health on the Net Foundation Institute of Cancer Research Medical Research Council NHS Direct World Health Organisation Printable version | Send it to a friend | Save story
| |||||||||||||||||
|
|
|
|
|
|
|
